Is CRDF a buy today

**Cardiff Oncology (CRDF) is not a buy today based on the provided analysis**. Here's why:

1. **Financial Performance**: CRDF reported a quarterly loss of $0.25 per share, which is an improvement from the previous year's loss of $0.22 per share. However, the company's P/E ratio is negative at -4.41, indicating that it is not currently profitable and is not an attractive buy based on earnings.
2. **Technical Analysis**: The stock's technical indicators are mixed. The RSI is high at 91.9, suggesting that the stock may be overbought. The MACD is 0.22, and the KDJ is 91.38, both of which could indicate a potential reversal or consolidation. The Bollinger Bands are at 3.06, which could suggest that the stock is trading in the upper part of its recent range and may be due for a pullback.

3. **Market Sentiment**: There has been a significant increase in short interest in CRDF, with a growth of 7.2% in October. This could indicate that investors are cautious or bearish on the stock.
4. **Strategic Position**: CRDF is actively enrolling patients in clinical trials, but there are uncertainties in the company's strategic direction, particularly in ovarian cancer. This could impact the company's future prospects.
5. **Cash Burn and Financial Position**: While CRDF has a cash runway through the end of the third quarter of 2025, there are concerns about cash burn and the sustainability of its immediate price movement based on earnings expectations.
6. **Institutional Activity**: There has been a reduction in shares held by Assenagon Asset Management S.A., indicating a potential lack of confidence in the stock's short-term performance.

In conclusion, while there are some positive aspects to CRDF's profile, such as an improvement in financial performance and potential for clinical trial success, the negative P/E ratio, technical indicators, and market sentiment suggest that it is not a buy today. Investors should exercise caution and consider the risks before investing in CRDF.